Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: Clinical and biomarker analysis

Eric Jonasch, Paul Corn, Lance C. Pagliaro, Carla L. Warneke, Marcella M. Johnson, Pheroze Tamboli, Chaan Ng, Ana Aparicio, Robynne G. Ashe, John J. Wright, Nizar M. Tannir

Research output: Contribution to journal › Article › peer-review

105 Scopus citations

Fingerprint

Dive into the research topics of 'Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: Clinical and biomarker analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences